Please try another search
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Name | Age | Since | Title |
---|---|---|---|
Bernd Robert Seizinger | 66 | 2014 | Director |
Trygve Lauvdal | 55 | - | Observer to the Board |
Birgitte Volck | 62 | 2021 | Director |
Christian Åbyholm | - | 2020 | Director |
Harald Arnet | - | 2023 | Director |
Einar Jorgen Greve | 64 | 2020 | Deputy Board Member |
Anne Michelle Clem Whitaker | 57 | 2022 | Director |
Alf Gunnar Martin Nicklasson | 69 | - | Chairman of the Board |
Elaine Sullivan | 63 | 2022 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review